natgillin/translations-raw huggingface dataset:
EU/1/02/231/017 1 cartridge of 3 ml EU/1/02/231/018 5 cartridges of 3 ml EU/1/02/231/019 10 cartridges of 3 ml
EU/1/02/231/017 1 vložek s 3 ml EU/1/02/231/018 5 vložkov s 3 ml EU/1/02/231/019 10 vložkov s 3 ml
► If you suspect hypoglycaemia (low blood sugar) is starting, see Summary of serious and very common side effects in section 4.
Ne uporabljajte zdravila Mixtard: ► če ste alergični na humani insulin ali katero koli sestavino tega zdravila, glejte poglavje 6, ► če domnevate, da se vam je začel krvni sladkor zniževati (pojav hipoglikemije), glejte podpoglavje Povzetek resnih in zelo pogostih neželenih učinkov v poglavju 4, ► v insulinskih infuzijskih črpalkah, ► če zaščitna zaporka ni trdno pričvrščena ali manjka.
Needles and Mixtard Penfill must not be shared.
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Injekcijskih igel in zdravila Mixtard Penfill se ne sme deliti z drugimi.
Mixtard 50 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 50 is essentially ‘sodiumfree'.
Pomožna snov z znanim učinkom: Zdravilo Mixtard 50 vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
Mixtard 30 Penfill 100 IU/ml Suspension for injection Insulin human
Mixtard 30 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Mixtard 30 FlexPen 100 IU/ml Suspension for injection Insulin human
Mixtard 30 FlexPen 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
- If the second and third characters are T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d'Orléans, F-28000 Chartres, France.
- Če sta drugi in tretji znak T6, je izdelovalec Novo Nordisk Production SAS,
Mixtard 40 Penfill 100 IU/ml Suspension for injection Insulin human
Mixtard 40 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Mixtard 50 Penfill 100 IU/ml Suspension for injection Insulin human
Mixtard 50 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Mixtard 50 Penfill 100 international units/ml suspension for injection in cartridge.
IME ZDRAVILA Mixtard 50 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku
Mixtard 30 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 30 is essentially ‘sodiumfree'.
Pomožna snov z znanim učinkom: Zdravilo Mixtard 30 vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
Read carefully the Instructions on how to use Mixtard 30 FlexPen included in this package leaflet.
Preberite še navodila za uporabo injekcijskega peresnika FlexPen na hrbtni strani tega navodila.
Mixtard 30 40 IU/ml Suspension for injection Insulin human SC
Mixtard 30 40 mednarodnih enot/ml suspenzija za injiciranje humani insulin za s.c. uporabo
EU/1/02/231/030 1 pen of 3 ml EU/1/02/231/031 5 pens of 3 ml EU/1/02/231/032 10 pens of 3 ml
EU/1/02/231/030 1 peresnik s 3 ml EU/1/02/231/031 5 peresnikov s 3 ml EU/1/02/231/032 10 peresnikov s 3 ml
Mixtard 40 contains less than 1 mmol sodium (23 mg) per dose, i.e. Mixtard 40 is essentially ‘sodiumfree'.
Pomožna snov z znanim učinkom: Zdravilo Mixtard 40 vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni “brez natrija”.
Mixtard 30 100 IU/ml Suspension for injection Insulin human SC
Mixtard 30 100 mednarodnih enot/ml suspenzija za injiciranje humani insulin za s.c. uporabo
Mixtard 30 InnoLet 100 IU/ml Suspension for injection Insulin human
Mixtard 30 InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Mixtard 40 Penfill 100 international units/ml suspension for injection in cartridge.
IME ZDRAVILA Mixtard 40 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku
Package leaflet: Information for the user Mixtard 30 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Navodilo za uporabo Mixtard 30 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Package leaflet: Information for the user Mixtard 30 40 IU/ml (international units/ml) suspension for injection in vial human insulin
Navodilo za uporabo Mixtard 30 40 mednarodnih enot/ml suspenzija za injiciranje v viali humani insulin
Package leaflet: Information for the user Mixtard 40 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Navodilo za uporabo Mixtard 40 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Package leaflet: Information for the user Mixtard 50 Penfill 100 IU/ml (international units/ml) suspension for injection in cartridge human insulin
Navodilo za uporabo Mixtard 50 Penfill 100 mednarodnih enot/ml suspenzija za injiciranje v vložku humani insulin
Mixtard 30 vial (40 international units/ml)/Mixtard 30 vial (100 international units/ml) Vial (type 1 glass) closed with a disc (bromobutyl/polyisoprene rubber) and a protective tamper-proof plastic cap containing 10 ml of suspension.
Viala (steklo tipa 1), zaprta z zamaškom (bromobutil/poliizoprenska guma) in zaščitena z varnostno plastično zaporko, ki vsebuje 10 ml suspenzije.
Package leaflet: Information for the user Mixtard 30 FlexPen 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Navodilo za uporabo Mixtard 30 FlexPen 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
Package leaflet: Information for the user Mixtard 30 100 IU/ml (international units/ml) suspension for injection in vial human insulin
Navodilo za uporabo Mixtard 30 100 mednarodnih enot/ml suspenzija za injiciranje v viali humani insulin
Package leaflet: Information for the user Mixtard 30 InnoLet 100 IU/ml (international units/ml) suspension for injection in pre-filled pen human insulin
Navodilo za uporabo Mixtard 30 InnoLet 100 mednarodnih enot/ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku humani insulin
- If the second and third characters are S6 or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
Izdelovalca je mogoče ugotoviti po serijski številki, natisnjeni na škatli in nalepki: - Če sta drugi in tretji znak S6 ali ZF, je izdelovalec Novo Nordisk A/S, Novo Allé, DK
Mixtard 30 40 international units/ml suspension for injection in vial.
Mixtard 30 40 mednarodnih enot/ml suspenzija za injiciranje v viali Mixtard 30 100 mednarodnih enot/ml suspenzija za injiciranje v viali
EU/1/02/231/033 1 pen of 3 ml EU/1/02/231/034 5 pens of 3 ml EU/1/02/231/035 10 pens of 3 ml
EU/1/02/231/033 1 peresnik s 3 ml EU/1/02/231/034 5 peresnikov s 3 ml
Ebixa should be given once a day at the same time every day.
Zdravilo Ebixa se daje enkrat dnevno, vsak dan ob istem času.
The European Commission granted a marketing authorisation valid throughout the European Union for Ebixa on 15 May 2002.
Evropska komisija je dovoljenje za promet z zdravilom Ebixa, veljavno po vsej Evropski uniji, odobrila dne 15. maja 2002.
The full EPAR for Ebixa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ebixa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
To prevent side effects, the dose of Ebixa is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Da se preprečijo neželeni učinki, se odmerek zdravila Ebixa v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat dnevno.
Other information about Ebixa
Druge informacije o zdravilu Ebixa
For more information about treatment with Ebixa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ebixa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This is a summary of the European public assessment report (EPAR) for Ebixa.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ebixa.
The most common side effects with Ebixa (seen in between 1 and 10 patients in 100) are somnolence (sleepiness), dizziness, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, headache and drug hypersensitivity (allergy to the medicine).
Najpogostejši neželeni učinki zdravila Ebixa (opaženi pri 1 do 10 bolnikih od 100) so somnolenca (zaspanost), omotica, hipertenzija (visok krvni tlak), dispneja (oteženo dihanje), zaprtje, glavobol in preobčutljivost (alergija na zdravilo).
However, when these results were considered along with those of the three additional studies, it was noted that the effect of Ebixa was smaller in patients with mild disease.
Vendar pa je bilo s primerjavo teh rezultatov z rezultati treh dodatnih študij ugotovljeno, da je bil učinek zdravila Ebixa manjši pri bolnikih z blago boleznijo.
Ebixa is used to treat patients with moderate to severe Alzheimer's disease.
Zdravilo Ebixa se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Ebixa was more effective than placebo at controlling the symptoms of Alzheimer's disease.
Zdravilo Ebixa je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Ebixa should be reassessed on a regular basis.
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Ebixa ponovno ocenjevati v rednih intervalih.
What benefit has Ebixa shown during the studies?
Kakšne koristi je zdravilo Ebixa izkazalo med študijami?
Ebixa has been studied in three main studies including a total of 1,125 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past.
Zdravilo Ebixa so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
Ebixa was compared with placebo (a dummy treatment) over 24 to 28 weeks.
Zdravilo Ebixa so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju 24 do 28 tednov.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Ebixa by the patient.
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Ebixa.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ebixa.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Ebixa, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP decided that Ebixa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ebixa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Ebixa should not be used in people who may be hypersensitive (allergic) to memantine hydrochloride or any of the other ingredients.
Zdravila Ebixa ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) memantinijev klorid ali katero koli drugo sestavino zdravila.
Ebixa was also studied in three additional studies including a total of 1,186 patients with mild to severe disease.
Zdravilo Ebixa so proučevali še v treh dodatnih študijah, ki so vključevale skupno 1 186 bolnikov z blago do hudo boleznijo.
Ebixa is also available as an oral solution, which is supplied with a pump that delivers 5 mg memantine hydrochloride with each activation.
Zdravilo Ebixa je na voljo tudi kot peroralna raztopina z dodano črpalko, ki dovaja 5 mg memantinijevega klorida ob vsakem črpanju.
In the two studies of mild to moderate disease, patients on Ebixa had less severe symptoms after 24 weeks, as measured on the global and cognitive scores.
V dveh študijah blage do zmerne bolezni so imeli bolniki, ki so prejemali zdravilo Ebixa, po 24 tednih manj hudih simptomov, merjeno z globalnimi in kognitivnimi merili.
What is the risk associated with Ebixa?
Kakšna tveganja so povezana z zdravilom Ebixa?
In the study of moderately severe to severe disease, patients taking Ebixa had fewer symptoms than those taking placebo after 28 weeks, as measured on both global and functional scores.
V študiji z bolniki z zmerno hudo do hudo boleznijo je bilo po 28 tednih pri bolnikih, ki so jemali zdravilo Ebixa, ugotovljenih manj simptomov kot pri bolnikih, ki so jemali placebo, merjeno z globalnimi in funkcionalnimi merili.
For the full list of all side effects reported with Ebixa, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ebixa, glejte navodilo za uporabo.
Ebixa is a medicine that contains the active substance memantine hydrochloride.
Ebixa je zdravilo, ki vsebuje zdravilno učinkovino memantinijev klorid.
The active substance in Ebixa, memantine hydrochloride, is an antidementia medicine.
Zdravilna učinkovina zdravila Ebixa, memantinijev klorid, je zdravilo za zdravljenje demence.
Why has Ebixa been approved?
Zakaj je bilo zdravilo Ebixa odobreno?
How has Ebixa been studied?
Kako je bilo zdravilo Ebixa raziskano?
What is Ebixa used for?
Za kaj se zdravilo Ebixa uporablja?
How does Ebixa work?
Kako zdravilo Ebixa deluje?
What is Ebixa?
Kaj je zdravilo Ebixa?
How is Ebixa used?
Kako se zdravilo Ebixa uporablja?
This summary was last updated in 02-2017.
Povzetek je bil nazadnje posodobljen 02-2017.
Metformin has been available in the EU since the 1950s.
Metformin je v EU na voljo od petdesetih let prejšnjega stoletja.
Doses are adjusted as necessary.
Odmerka se po potrebi prilagodita.
Supportive evidence was provided from several further studies.
Več nadaljnjih študij je ponudilo podporne dokaze.
What measures are being taken to ensure the safe and effective use of Synjardy?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Synjardy?
The European Commission granted a marketing authorisation valid throughout the European Union for Synjardy on 27 May 2015.
Evropska komisija je dovoljenje za promet z zdravilom Synjardy, veljavno po vsej Evropski uniji, izdala 27. maja 2015.
• liver impairment, or problems with alcoholism or alcohol intoxication.
• jetrno okvaro ali težavami z alkoholizmom ali zastrupitvijo z alkoholom.
The full EPAR and risk management plan summary for Synjardy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Synjardy sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Some of these were continuations of the main studies that suggested the benefits of the combination continued with longer therapy.
Med nekatere od njih spadajo nadaljevanje glavnih študij, v katerih so zabeležili, da so se koristi kombinacije nadaljevale z daljšim zdravljenjem.
This is a summary of the European public assessment report (EPAR) for Synjardy.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Synjardy.
Synjardy must not be used in patients with:
Zdravila Synjardy ne smejo uporabljati bolniki z:
Empagliflozin has been authorised in the EU under the trade name Jardiance since 2014.
Empagliflozin je s tržnim imenom Jardiance v EU odobren od leta 2014.
This leads to a high level of glucose in the blood.
To vodi do visoke ravni glukoze v krvi.
• in patients who are already taking metformin and empagliflozin as separate tablets.
• pri bolnikih, ki že jemljejo metformin in empagliflozin v obliki ločenih tablet.
It is not intended to provide practical advice on how to use Synjardy.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Synjardy večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The main measure of effectiveness was the reduction in the level of a substance in the blood called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment.
Glavno merilo učinkovitosti je bilo zmanjšanje količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), po 24 tednih zdravljenja.
• metabolic acidosis (when the body produces more acid than it gets rid of) or diabetic pre-coma (dangerous complications of diabetes);
• metabolično acidozo (kadar telo tvori več kisline kot je izloči) ali diabetično predkomo (nevarnima zapletoma sladkorne bolezni);
In addition, the results indicated that the combination was associated with a beneficial decrease in body weight and blood pressure.
Poleg tega so rezultati pokazali, da je zdravljenje s kombinacijo zdravil povezano s koristnim zmanjšanjem telesne mase in krvnega tlaka.
Because of concerns about the balance of benefit and risk in patients with reduced kidney function taking the fixed-dose combination, the CHMP recommended restricting its use in these patients.
Zaradi pomislekov glede razmerja med tveganji in koristmi pri bolnikih z zmanjšanim delovanjem ledvic, ki jemljejo fiksno kombinacijo odmerkov, je odbor CHMP priporočil omejitev njegove uporabe pri teh bolnikih.
Other information about Synjardy
Druge informacije o zdravilu Synjardy
Among these, in patients who were also taking metformin (the other active substance in Synjardy), the three major cardiovascular events occurred in 9.9% (344 out of 3,459) of patients receiving empagliflozin and in 10.9% (189 out of 1,734) of patients receiving placebo.
Med njimi so se pri bolnikih, ki so jemali tudi metformin (drugo zdravilno učinkovino zdravila Synjardy), trije glavni kardiovaskularni dogodki pojavili pri 9,9 % (344 od 3 459) bolnikov, ki so prejemali empagliflozin, in 10,9 % (189 od 1 734) bolnikov, ki so prejemali placebo.
What are the risks associated with Synjardy?
Kakšna tveganja so povezana z zdravilom Synjardy?
What benefits of Synjardy have been shown in studies?
Kakšne koristi je zdravilo Synjardy izkazalo v študijah?
What is Synjardy and what is it used for?
Kaj je zdravilo Synjardy in za kaj se uporablja?
The recommended dose of Synjardy is one tablet twice a day with meals, and treatment is normally started with a tablet that supplies the dose of metformin the patient is already taking, together with the lowest dose (5 mg) of empagliflozin.
Priporočeni odmerek zdravila Synjardy je ena tableta dvakrat na dan ob obrokih, zdravljenje pa se navadno začne s tableto, ki vsebuje odmerek metformina, ki ga bolnik že jemlje, in najmanjši odmerek (5 mg) empagliflozina.
Similar benefits were seen in the studies regardless of the other diabetes medicines being taken.
V študijah so opazili podobne koristi, ne glede na drugo zdravilo za zdravljenje sladkorne bolezni, ki so ga jemali bolniki.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Synjardy have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Synjardy upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Synjardy is used:
Zdravilo Synjardy se uporablja:
Why is Synjardy approved?
Zakaj je bilo zdravilo Synjardy odobreno?
The benefits of empagliflozin in combination with metformin have been shown in 3 main studies involving 1,679 patients with type 2 diabetes whose blood sugar was not adequately controlled by metformin, alone or combined with other diabetes medicines (such as pioglitazone or a type of diabetes medicine called a sulphonylurea).
Koristi kombinacije empagliflozina in metformina so dokazali v treh glavnih študijah, ki so vključevale 1 679 bolnikov s sladkorno boleznijo tipa 2, pri katerih sladkor v krvi ni bil zadostno uravnan s samostojnim metforminom ali metforminom v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni (kot sta pioglitazon ali druga vrsta zdravila za zdravljenje sladkorne bolezni, sulfonilsečnina).
For more information about treatment with Synjardy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Synjardy preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
• severely reduced kidney function or conditions that could affect the kidneys such as dehydration, severe infection or a steep fall in blood pressure;
• močno zmanjšanim delovanjem ledvic ali stanji, ki lahko vplivajo na ledvice, kot so dehidracija, huda okužba ali nenaden padec krvnega tlaka;
Metformin works mainly by reducing the production of glucose in the body and reducing its absorption from the gut.
Metformin učinkuje predvsem tako, da zmanjšuje tvorjenje glukoze v telesu in njeno absorbcijo iz črevesa.
In those receiving empagliflozin, cardiovascular events occurred in 10.5% (490 out of 4,687) of patients compared with 12.1% (282 out of 2,333) of patients receiving placebo.
Kardiovaskularni dogodki so se pojavili pri 10,5 % (490 od 4 687) bolnikov, ki so prejemali empagliflozin, v primerjavi z 12,1 % (282 od 2 333)
• a condition that could reduce the supply of oxygen to body tissues (such as in patients with worsening heart failure, recent heart attack, breathing difficulty or a steep fall in blood pressure);
• obolenjem, ki lahko zmanjša dovajanje kisika v tkiva (npr. pri bolnikih, pri katerih se slabša srčno popuščanje, pri tistih, ki so pred kratkim doživeli srčni napad, imajo oteženo dihanje ali nenaden padec krvnega tlaka);
In type 2 diabetes the body does not make enough insulin to control the level of glucose (sugar) in the blood or the body is unable to use insulin effectively.
Pri sladkorni bolezni tipa 2 telo ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze (sladkorja) v krvi ali ga telo ne more učinkovito izrabiti.
• in patients whose diabetes is not sufficiently controlled by metformin alone;
• pri bolnikih, pri katerih sladkorna bolezen ni zadovoljivo uravnana samo z metforminom;
For practical information about using Synjardy, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Synjardy naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Another main study showed that adding empagliflozin (one of the active substances of Synjardy) to usual treatment reduced adverse cardiovascular (heart and blood vessels) effects.
Druga glavna študija je pokazala, da dodajanje empagliflozina (ene od zdravilnih učinkovin zdravila Synjardy) običajnemu zdravljenju, zmanjšuje neželene kardiovaskularne učinke (učinke na srce in ožilje).
Empagliflozin works by blocking a protein in the kidneys (called sodium-glucose co-transporter 2 or SGLT2).
Empagliflozin deluje tako, da zavira beljakovino v ledvicah (imenovano natrijev glukozni koprenašalec 2 ali SGLT2).